All In Biotech

Drug Trial Radar · NCT04650984

A Study Comparing the Efficacy of L19TNF+Doxorubicin vs Doxorubicin Alone as First-line Therapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma

A Phase III Study Comparing the Efficacy of the Combination of Doxorubicin and the Tumor-targeting Human Antibody-cytokine Fusion Protein L19TNF to Doxorubicin Alone as First-line Therapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma

Last checked: Nov 19, 2026Latest source record: Apr 8, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 102 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

102

Planned (sponsor's estimate)

Start

Nov 29, 2017

Primary completion

Dec 31, 2025

Study completion Dec 31, 2025

Sponsor

Lead sponsor
Philogen S.p.A.Industry
Sponsor type
Industry
First posted
Dec 3, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The present study is an open-label, randomized, controlled, two-arm multi-center study of the efficacy of L19TNF treatment in combination with doxorubicin versus doxorubicin alone in advanced or metastatic soft-tissue sarcoma patients. In the study, 102 patients will be randomized in a 1:1 ratio to receive doxorubicin treatment (Arm 1) or L19TNF treatment in combination with doxorubicin (Arm 2). The primary objective of the trial is to evaluate if L19TNF in combination with doxorubicin (Arm 2) given for unresectable or metastatic soft tissue sarcoma improves efficacy measured as progression free survival, as compared to doxorubicin alone (Arm 1).

Conditions

  • Soft Tissue Sarcoma

Interventions

  • Onfekafusp alfaDrug

    Patients will receive a fixed dose of L19TNF in combination with a fixed dose of doxorubicin.

  • DoxorubicinDrug

    Patients will receive a fixed dose doxorubicin, administered as a 15 ± 5 minutes i.v. infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Median Progression free survival (mPFS)Time frame: From randomization up to week 72

Locations

28 sites in 5 countries. Site status is shown where the registry gives one.

  • Institut Bergonié

    Bordeaux, France · Recruiting

  • Centre Georges François Leclerc

    Dijon, France · Recruiting

  • Centre Léon Bérard

    Lyon, France · Recruiting

  • Centre Antoine Lacassagne

    Nice, France · Recruiting

  • Institut Claudius Regaud

    Toulouse, France · Not yet recruiting

  • Institut Gustave Roussy

    Villejuif, France · Not yet recruiting

  • Helios Klinikum Bad Saarow

    Bad Saarow, Germany · Recruiting

  • Charité- Universitätsmedizin Berlin

    Berlin, Germany · Recruiting

  • Uniklinik Köln

    Cologne, Germany · Recruiting

  • Universitätsklinikum Düsseldorf

    Düsseldorf, Germany · Not yet recruiting

  • Universitätsklinikum Frankfurt

    Frankfurt, Germany · Recruiting

  • Universitätsklinik Hamburg-Eppendorf

    Hamburg, Germany · Recruiting

  • Heidelberg University Hospital

    Heidelberg, Germany · Recruiting

  • Universitätsmedizin der J.-G. Universität Mainz

    Mainz, Germany · Recruiting

  • Klinik rechts der Isar

    München, Germany · Recruiting

  • Universitaetsklinikum Muenster

    Münster, Germany · Recruiting

  • Bologna University, Chemotherapy Unit, IRCCS Istituto Ortopedico Rizzoli, Department of DIMES

    Bologna, Italy · Recruiting

  • AOU San Luigi Gonzaga

    Orbassano, Italy · Not yet recruiting

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS

    Roma, Italy · Not yet recruiting

  • IRCCS Fondazione del Piemonte per l'Oncologia Istituto per la Ricerca e la Cura del Cancro di Candiolo

    Candiolo, Torino, Italy · Recruiting

  • Szpital Pomorski Im. PCK

    Gdynia, Poland · Not yet recruiting

  • Centrum Onkologii-Instytut im. Marii Skłodowskiej-Curie Warszawa

    Warsaw, Poland · Recruiting

  • Hospital Universitari Vall d'Hebron

    Barcelona, Spain · Recruiting

  • Hospital Universitario Virgen de las Nieves

    Granada, Spain · Recruiting

  • Fundación Jiménez Díaz

    Madrid, Spain · Recruiting

  • Hospital General Universitario Gregorio Marañón

    Madrid, Spain · Recruiting

  • Hospital Miguel Servet

    Zaragoza, Spain · Recruiting

  • Hospital Universitario Virgen de la Arrixaca

    El Palmar, Murcia, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.